Alkem

Motilal Oswal recommended Neutral rating on alkem with a target price of Rs 6030 in its research report dated September 03, 2024.

US FDA releases details of observations on Alkem's Baddi Plant

The US FDA had conducted an inspection of the facility last month and had made ten procedural observations, including issues with cleanliness and the company's failure to keep written documents on quality control procedures.

Sun Pharma, Lupin, Alkem recall products from US market

Sun Pharma is recalling 54,960 bottles of Mesalamine Extended-Release Capsules, an anti-inflammatory medicine used to treat a type of bowel disease known as ulcerative colitis

Neutral Alkem; target of Rs 5160: Motilal Oswal

Motilal Oswal recommended Neutral rating on Alkem with a target price of Rs 5160 in its research report dated February 21, 2024.

Pharma firm Alkem launches drive to raise awareness about early diagnosis, treatment of respiratory ailments

'Access to prevention and treatment for all. Leave no one behind is the theme of this year's World Lung Day.

Indian pharma industry may rebound to 8-11% growth rate: Alkem

Alkem Laboratories believes that inflationary pressures and changing regulatory norms will be the main issues to watch out for when the pandemic eases, and that the Indian pharmaceutical business will recover to 8–11% growth rate with normalcy in activities.

Buy Alkem; target of Rs 3870 : Motilal Oswal

Motilal Oswal is bullish on Alkem recommended buy rating on the stock with a target price of Rs 3870 in its research report dated March 07, 2022.

Buy Alkem; target of Rs 3730: Motilal Oswal

Motilal Oswal is bullish on Alkem recommended buy rating on the stock with a target price of Rs 3730 in its research report dated Jun 07, 2021.

Ideas For Profit | What the second covid-19 ‘wave’ means for domestic pharma companies?

With the second Covid ‘Wave’ already surpassing the daily highs recorded in the month of September 2020 of about 95000, the demand for vaccines, critical medical equipment like vaccines, oxygen cylinders and ventilators have increased manifold. Watch the video to know what this evolving situation means for Indian Pharma?

Alkem: A good lesson for attention bias

With Alkem, the attention bias was on the newness, the fundamental story, the lack of ownership and minimal research coverage leading to limited information flow

Havas Group acquires healthcare agency Sorento

Sorento will partner with 'Havas Health and You' business unit and be rebranded Havas Life Sorento, the agency said in a statement.

Alkem Q4 PAT may dip 42.8% to Rs 133.6 cr: ICICI Securities

Net Sales are expected to decrease by 10.1 percent Q-o-Q (up 16.5 percent Y-o-Y) to Rs 1331.5 crore, according to ICICI Securities. Alkem to report net profit at 133.6 crore down 42.8% quarter-on-quarter.

Will submit clarification to EMA on clinical study data:Alkem

Drug maker Alkem Laboratories today said it will submit 'suitable clarifications' to the European Medicines Agency (EMA) over a decision by the drug regulator to review two drugs for which clinical trial studies were conducted by the Mumbai-based firm.

Accumulate RComm at lower levels: Dilip Bhat

Dilip Bhat of Prabhudas Lilladher recommends accumulating Reliance Communication at lower levels.

Alkem Labs eyes $210 mn IPO in Dec: Sources

Alkem Labs' share sale will be India's third high-profile market debut in the last three months of 2015, after airline IndiGo raised USD 459 million and Coffee Day Enterprises raised USD 176 million.

India's big name market debuts belie thin IPO pipeline

Bankers say volatile global markets and a tepid performance at home are scaring off potential candidates. Worse, few obvious big names remain after a wave of listings in 2010, when Indian markets were riding high.